OIE Reference Laboratory Reports
Activities in 2012
Name of disease (or topic) for which you
are a designated OIE Reference
Laboratory:
Marek’s disease
Address of laboratory
USDA-ARS Avian Disease and Oncology Laboratory
4279 East Mount Hope Road
East Lansing, Michigan 48823 USA
Tel.:
517-337-6828
Fax:
517-337-6776
e-mail address:
FADLY@MSU.EDU
ALY.FADLY@ARS.USDA.GOV
website:
http://www.ars.usda.gov/mwa/lansing/adol
Name (including Title) of Head of
Laboratory (Responsible Official):
Dr. ALY M. FADLY
Name (including Title and Position) of OIE
Reference Expert:
Dr. ALY M. FADLY
Date of submission to the OIE
January 16, 2013
Research Leader and Laboratory Director
Research Leader and Laboratory Director
Instructions
This form should be used by an OIE Reference Laboratory to report activities that took place from January
through December of the past year (2012), unless otherwise stated, and must be submitted by the end of
January every year.
Only those activities that concern the disease (or topic) for which the laboratory is recognised by the OIE
should be mentioned. The questionnaire structure follows the Terms of Reference (ToRs) for OIE Reference
Laboratories, available at:
http://www.oie.int/en/our-scientific-expertise/reference-laboratories/introduction/
Each ToR (blue italicised text) has been placed as a heading covering the group of questions related to it.
Please note the red italicised text is given as guidance and should be deleted from your report and substitute
with your data. Examples are based on past Annual Reports or have been invented.
The questionnaire represents a means of gathering information on activities carried out by OIE Reference
Laboratories and making it available to OIE Member Countries and to the OIE Reference Laboratory network.
This annual report will remain available for consultation on the OIE web site:
(http://www.oie.int/en/our-scientific-expertise/reference-laboratories/annual-reports/):
Annual reports of OIE Reference Centres, 2012
1
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
ToR = OIE Term of Reference
ToR: To use, promote and disseminate diagnostic methods validated according to OIE
Standards
Test recommended by the OIE
Total number of test performed last year
Indirect diagnostic tests
Nationally
Internationally
IFA using monoclonal antibodies
20
0
Direct diagnostic tests
Nationally
Internationally
Cell Culture
45
0
PCR
35
0
ToR: To develop reference material in accordance with OIE requirements, and implement
and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any
other reagents used in the diagnosis and control of the designated pathogens or
disease.
2.
Did your laboratory produce or store imported standard reference reagents officially recognised
by the OIE or other international bodies?
Yes
3.
No
Did your laboratory supply standard reference reagents to OIE Member Countries?
Yes
No
Name of
recipient OIE
Member
Countries and
of institutions
Related
diagnostic
test
Produce
d/
stored
Amount supplied
nationally
(ml, mg)
Amount supplied
internationally
(ml, mg)
Control positive
DNA
PCR
Produced
1 mg
0
USA
(Pennsylvania
State University)
Monoclonal
antibodies
IHC, FA
Produced
6 ml
5 ml
USA (University of
Iowa)
Type of reagent
available
China (South
China Agricultural
University)
Prototype of very
virulent strain of
Marek’s disease
virus
2
Challenge
experiments
Produced
/stored
0
6 ml
France (University
of Tours)
Annual reports of OIE Reference Centres, 2012
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
Type of reagent
available
Related
diagnostic
test
HVT/Fowl Pox
recombinant virus
HVT
neutralization
4.
Produce
d/
stored
Produced
Amount supplied
nationally
(ml, mg)
0
USA (USDA-APHIS
Center for
Veterinary
Biologics)
Did your laboratory produce diagnostic reagents other than the OIE-approved standard reference
reagents?
No
Did your laboratory produce vaccines?
Yes
6.
Name of
recipient OIE
Member
Countries and
of institutions
3 ml
Yes
5.
Amount supplied
internationally
(ml, mg)
No
Did your laboratory supply vaccines to OIE Member Countries?
Yes
Vaccine name
No
Amount supplied nationally
(ml, mg) (including for own
use)
Amount supplied to
other countries (ml, mg)
Name of recipient
OIE Member
Countries
75 ml
0
Own use
Marek’s disease vaccine
strains (HVT,
recombinant HVT
strains, SB1, Rispens)
ToR: To develop, standardise and validate, according to OIE Standards, new procedures for
diagnosis and control of the designated pathogens or diseases
7.
Did your laboratory develop new diagnostic methods validated according to OIE Standards for the
designated pathogen or disease?
Yes
8.
No
Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen
or disease?
Yes
Name of the new test or diagnostic
method or vaccine developed
Polymerase Chain Reaction (PCR) for
Diagnosis of Marek’s Disease in FormalinFixed, Paraffin- Embedded Tumorous
Tissues
Annual reports of OIE Reference Laboratories, 2012
No
Description and References (Publication, website, etc.)
Use of Polymerase Chain Reaction (PCR) in Diagnosis of
Marek’s Disease and Reticuloendotheliosis in FormalinFixed, Paraffin- Embedded Tumorous Tissues. 2012.
Proceedings American Veterinary Medical Association ;
149th AVMA Annual Convention, August 3-7. San Diego,
CA. (To be submitted to peer-reviewed journal)
3
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
Attenuated rMd5ΔMeq vaccine candidate
Lee, L. F., M. Heidari, H. M. Zhang, B. Lupiani, S. M.
Reddy, and A. Fadly. Cell culture attenuation eliminates
rMd5ΔMeq-induced bursal and thymic atrophy and renders
the mutant virus as an effective and safe vaccine against
Marek's disease. Vaccine. 30:5151-5158. 2012.
ToR: To provide diagnostic testing facilities, and, where appropriate, scientific and
technical advice on disease control measures to OIE Member Countries
9.
Did your laboratory carry out diagnostic testing for other OIE Member Countries?
Yes
10.
No
Did your laboratory provide expert advice in technical consultancies on the request of an OIE
Member Country?
Yes
Name of the OIE Member Country
receiving a technical consultancy
No
How the advice was
provided
Purpose
Australia
Case of transient paralysis in broilers
refractory to HVT vaccination
By email
Guatemala
Marek’s disease virus cell culture
procedures
By email
Germany & Hungary
Current status of global MD incidence
By email
ToR: To carry out and/or coordinate scientific and technical studies in collaboration with
other laboratories, centres or organisations
11.
Did your laboratory participate in international scientific studies in collaboration with OIE Member
Countries other than the own?
Yes
Title of the study
Study of distribution
of Neoplastic Diseases
of Retroviral Etiology
of birds in
Commercial Poultry
Farms of Russian
Federation
4
Duration
5 years
No
Purpose of the study
Objectives include:
Development of a new
diagnostic test for detection
and differentiation of
retroviral tumors from other
causative agents of
neoplastic diseases based on
PCR and real-time PCR
Partners
(Institutions)
NARVAC R&D
Department, D.I.
Ivanovski Virology
Institute, Moscow and
Federal Research
Institute in Validmir
OIE Member Countries
involved other than
your country
Russian Federation
Annual reports of OIE Reference Centres, 2012
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
ToR: To collect, process, analyse, publish and disseminate epizootiological data relevant to
the designated pathogens or diseases
12.
Did your Laboratory collect epizootiological data relevant to international disease control?
Yes
13.
No
Did your laboratory disseminate epizootiological data that had been processed and analysed?
Yes
14.
No
What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)
a)
Articles published in peer-reviewed journals: ................. 13
b)
International conferences: .............................................. 2
c)
National conferences: ...................................................... 2
d)
Other: ............................................................................... Am. Assoc. of Avian Pathologists-web
page
ToR: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards
15.
Did your laboratory provide scientific and technical training to laboratory personnel from other OIE
Member Countries?
Yes
No
If the answer is yes, please provide the total number of trained persons for each of the following
categories:
a)
Technical visits: ................................................................ 6
b)
Seminars: ......................................................................... 0
c)
Hands-on training courses: .............................................. 0
d)
Internships (>1 month): ................................................... 2
Type of technical training
provided (a, b, c or d)
Country of origin of the expert(s)
provided with training
No. participants from the
corresponding country
a
China
4
India
1
Turkey
1
USA
2
d
ToR: To maintain a system of quality assurance, biosafety and biosecurity relevant for the
pathogen and the disease concerned
16.
Does your laboratory have a Quality Management System certified according to an International
Standard?
Annual reports of OIE Reference Laboratories, 2012
5
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
Yes
No
Quality management system adopted
USDA-APHIS
17.
Is your laboratory accredited by an international accreditation body?
Yes
No
18. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease
concerned? (See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2012, Chapter 1.1.3 or
Manual of Diagnostic Tests for Aquatic Animals 2012, Chapter 1.1.1)
Yes
No
ToR: To organise and participate in scientific meetings on behalf of the OIE
19. Did your laboratory organise scientific meetings on behalf of the OIE?
Yes
20.
No
Did your laboratory participate in scientific meetings on behalf of the OIE?
Yes
No
ToR: To establish and maintain a network with other OIE Reference Laboratories
designated for the same pathogen or disease and organise regular inter-laboratory
proficiency testing to ensure comparability of results
21.
Did your laboratory exchange information with other OIE Reference Laboratories designated for the
same pathogen or disease?
Yes
22.
No
Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated
for the same pathogen or disease by organising or participating in proficiency tests?
Yes
23.
No
Did your laboratory collaborate with other OIE Reference Laboratories for the same disease
on scientific research projects for the diagnosis or control of the pathogen of interest?
Yes
No
Name(s) of relevant OIE
Reference Laboratories
Title of the project or contact
Scope
Materals Transfer Agreement
for exchange of materials
Agreed to supply BAC clone of prototype
MDV strain
IAH, OIE RL for MD, UK
ToR: To organise inter-laboratory proficiency testing with laboratories other than OIE
Reference Laboratories for the same pathogens and diseases to ensure equivalence of
results.
6
Annual reports of OIE Reference Centres, 2012
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
24.
Did your laboratory organise or participate in inter-laboratory proficiency tests with
laboratories other than OIE Reference Laboratories for the same disease?
Yes
No
ToR: To place expert consultants at the disposal of the OIE
25.
Did your laboratory place expert consultants at the disposal of the OIE?
Yes
No
__________
List of Publication on Marek’s disease
1.
Dunn, J.R., Silva, R.F., Lee, L.F., Witter, R.L. 2012. Competition between two virulent Marek's
disease virus strains in vivo. Avian Pathology. 41(3):267-275.
2.
Mays, J.K., Silva, R.F., Kim, T., Fadly, A.M. 2012. Insertion of reticuloendotheliosis virus long
terminal repeat into a bacterial artificial chromosome clone of a very virulent Marek's disease virus
alters its pathogenicity. Avian Pathology. 41(3):259-265
3.
Lee, L.F., Heidari, M., Zhang, H., Lupiani, B., Reddy, S.M., Fadly, A.M. 2012.Cell culture
attenuation eliminates rMd5deltaMeq-induced bursal and thymic atrophy and renders the mutant virus
as an effective and safe vaccine against Marek's disease. Vaccine. 30 (34):5151-5158.
4.
Yu, Y., Luo, J., Mitra, A., Chang, S., Tian, F., Zhang, H., Yuan, P., Zhou, H., Song, J. 2012.
Temporal transcriptome changes induced by MDV in Marek's disease-resistant and -susceptible
inbred chickens. Biomed Central (BMC) Genomics. 12:501. Available:
http://www.biomedcentral.com/1471-2164/12/501.
5.
Cheng, H.H., Maceachern, S., Subramaniam, S., Muir, W.M. 2012. Chicks and single-nucleotide
polymorphisms: an entree into identifying genes conferring disease resistance in chicken. Animal
Production Science. 52(3). Available: http://dx.doi.org/10.1071/AN11099.
6.
Chang, S., Dunn, J.R., Heidari, M., Lee, L.F., Ernst, C.W., Song, J., Zhang, H. 2012. Vaccine by
chicken line interaction alters the protective efficacy against challenge with a very virulent plus strain
of Marek's disease virus in white leghorn chickens. World Journal of Vaccines. 2(1):1-11.
7.
Luo, J., Yu, Y., Chang, S., Tian, F., Zhang, H., Song, J. 2012. DNA methylation fluctuation induced
by virus infection differs between MD resistant and -susceptible chickens. Frontiers in Genetics.
3(20):1-15.
8.
Tian, F., Luo, J., Zhang, H., Chang, S., Song, J. 2012. MiRNA expression signatures induced by
Marek disease virus infection in chickens. Genomics. 99 (3):152-159.
9.
Kumar, S., Kunec, D., Buza, J.J., Chiang, H.I., Zhou, H., Subramaniam, S., Pendarvis, K., Cheng,
H.H., Burgess, S.C. 2012. Nuclear Factor kappa B is central to Marek’s Disease herpesvirus induced
neoplastic transformation of CD30 expressing lymphocytes in-vivo. BMC Systems Biology. 6(123).
Available: http://www.biomedcentral.com/1752-0509/6/123.
10. Yuan, P., Yu, Y., Luo, J., Tian, F., Zhang, H., Chang, S., Ramachandran, R., Song, J. 2012.
Comparative study of lipoprotein metabolism in Marek's disease susceptible and resistant chickens.
Poultry Science. 91:2598-2605. Available: http://ps.fass.org/content/91/10/2598.
11. Fei, T., Luo, J., Zhang, H., Chang, S., Song, J. 2012. Marek's disease virus challenge induced
immune-related gene expression and chicken repeat 1 (CR1) methylation alterations in chickens.
American Journal of Molecular Biology (AJMB). 2(2012):232-241. Available:
http://www.scirp.org/journal/PaperInformation.aspx?paperID=20985.
Annual reports of OIE Reference Laboratories, 2012
7
OIE RL for « Marek’s Disease » – « Dr. Aly M. Fadly » – « USA »
12. Dunn, J.R., Silva, R.F. 2012. Ability of MEQ-deleted MDV vaccine candidates to adversely affect
lymphoid organs and chicken weight gain. Avian Diseases. 56:494-500.
13. Xu, M., Fitzgerald, S.D., Zhang, H., Karcher, D.M., Heidari, M. 2012. Very virulent plus strains of
MDV induce acute form of transient paralysis in both susceptible and resistant chicken lines. Viral
Immunology. 25(4):306-323.
8
Annual reports of OIE Reference Centres, 2012